AstraZeneca shares lead sector higher. Should you chase?

One of the rare bright spots among the UK large-caps is the pharma sector.

AstraZeneca (AZN), for example, is maintaining the upward pressure into new long-term highs following an explosive ‘breakaway gap’ on July 25 (see Featured Chart). When a stock exhibits such a pattern, be mindful of the powerful upward drift in the following weeks.

A competitor of Astra is GlaxoSmithKline (GSK). This stock, too, broke out to new long-term highs on July 29. But its relative strength is comparatively weaker against AZN. Prices rose to as high as 1740p before consolidating into its prior trading range at 1,600-1,640p. A positive note is that this consolidation is holding firm above the 50-day moving average.

At this point, we have to ask: Are these large-cap pharmas still a buy? Yield-wise, probably. AZN and GSK are yielding at around 2.9% and 4.7% respectively, higher than long-term gilts. But you have to be aware of the potential reversionary price moves in AZN after it had a four-week uptrend. Whilst the stock is still amidst a bull trend, wait for setbacks to add.

GSK, in comparison, is less overbought due to the regression to 1,640p. This stock has been a disappointment for many years. Prices are relatively flat with choppy moves. Bear in mind this characteristics when trading GSK.

 

Compare Vetted Investing, Trading & Currency Accounts

Investing AccountsTrading PlatformsCurrency Transfers
Compare Investment Accounts

Compare Investment Accounts

Compare Trading Platforms

Compare Trading Platforms

Compare Currency Brokers

Compare Currency Brokers

Trading Risk Warning

ALL INVESTING INVOLVES RISK. Investing, Derivatives, Spread betting and CFD trading carry a high level of risk to your capital and can result in losses that exceed your initial deposit. They may not be suitable for everyone, so please ensure that you fully understand the risks involved.
ESMA & FCA Risk Warning – “CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 68-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Capital at risk”